MX2017003370A - Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. - Google Patents
Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.Info
- Publication number
- MX2017003370A MX2017003370A MX2017003370A MX2017003370A MX2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A
- Authority
- MX
- Mexico
- Prior art keywords
- gep
- nen
- methods
- compositions
- kits
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G01N33/57557—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se proveen métodos de diagnóstico, detección o pronóstico de una GEP-NEN, basa-dos en la puntuación del grado de expresión de biomarcadores que exhiben expresión diferencial en sujetos que tienen una GEP-NEN con respecto a una muestra de referencia o control; la invención también provee composiciones y klts que comprenden estos biomarcadores y métodos de uso de estos biomarcadores en subconjuntos o paneles de los mismos para diagnosticar, clasificar y monito-rear GEP-NEN y tipos de GEP-NEN; los métodos y composiciones aquí provistos se pueden usar para diagnosticar o clasificar a un sujeto que tiene una GEP-NEN, para distinguir entre diferentes etapas de GEP-NEN, por ejemplo, estable o progresiva, para proveer una medida del riesgo de desarrollar una GEP-NEN progresiva, y para evaluar la complenitud de los tratamientos de GEP-NEN que inclu-yen, sin limitación, cirugía y terapia con somatostatina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050465P | 2014-09-15 | 2014-09-15 | |
| PCT/US2015/050274 WO2016044330A1 (en) | 2014-09-15 | 2015-09-15 | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017003370A true MX2017003370A (es) | 2017-11-22 |
| MX386919B MX386919B (es) | 2025-03-19 |
Family
ID=54207775
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003370A MX386919B (es) | 2014-09-15 | 2015-09-15 | Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática. |
| MX2021012347A MX2021012347A (es) | 2014-09-15 | 2017-03-14 | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012347A MX2021012347A (es) | 2014-09-15 | 2017-03-14 | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10407730B2 (es) |
| EP (2) | EP3929303B1 (es) |
| JP (2) | JP6782700B2 (es) |
| KR (2) | KR102762958B1 (es) |
| CN (1) | CN107208132A (es) |
| AU (3) | AU2015317893B2 (es) |
| CA (1) | CA2959670C (es) |
| DK (2) | DK3194618T3 (es) |
| ES (2) | ES2881474T3 (es) |
| IL (2) | IL250867B (es) |
| MX (2) | MX386919B (es) |
| PL (2) | PL3929303T3 (es) |
| WO (1) | WO2016044330A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3929303T3 (pl) | 2014-09-15 | 2025-04-28 | Clifton Life Sciences LLC | Kompozycje, sposoby i zestawy do diagnozy nowotworu neuroendokrynnego żołądkowo-jelitowo-trzustkowego |
| PL3631017T3 (pl) * | 2017-05-25 | 2022-09-26 | Liquid Biopsy Research LLC | Sposoby wykrywania czerniaka |
| IL317236A (en) * | 2017-11-30 | 2025-01-01 | Liquid Biopsy Res Llc | Predicting peptide receptor radiotherapy using gene expression testing |
| CN108048564B (zh) * | 2018-02-09 | 2021-03-05 | 中国科学院昆明动物研究所 | 人glt8d1基因的新用途 |
| CN112514001B (zh) * | 2018-07-30 | 2025-03-07 | 新加坡科技研究局 | 评价组织样本纤维化的方法和系统 |
| MX2022004372A (es) | 2019-10-10 | 2022-07-27 | Liquid Biopsy Res Llc | Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn. |
| FR3110764B1 (fr) | 2020-05-20 | 2024-05-10 | Quantum Surgical | Méthode de prédiction de la récidive d’une lésion par analyse d’images |
| CN113215255B (zh) * | 2021-04-26 | 2022-04-05 | 山东天川精准医疗科技有限公司 | 用于肝癌早期诊断或预后的生物标记物及其用途 |
| CN120153081A (zh) * | 2022-07-15 | 2025-06-13 | 埃门多生物公司 | Aplp2安全港位点敲入策略 |
| CN120380169A (zh) * | 2022-09-30 | 2025-07-25 | 液体活检研究有限责任公司 | 用于在唾液中检测神经内分泌癌的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050084883A1 (en) * | 2003-08-25 | 2005-04-21 | The Johns Hopkins University School Of Medicine | Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differential gene expression analysis |
| ES2750651T3 (es) | 2008-06-12 | 2020-03-26 | Ipsen Bioinnovation Ltd | Proteínas de fusión para uso en el tratamiento de acromegalia |
| CN103502473B (zh) * | 2011-03-01 | 2016-03-09 | 耶鲁大学 | 胃肠胰神经内分泌肿瘤(gep-nen)的预测 |
| PL3929303T3 (pl) | 2014-09-15 | 2025-04-28 | Clifton Life Sciences LLC | Kompozycje, sposoby i zestawy do diagnozy nowotworu neuroendokrynnego żołądkowo-jelitowo-trzustkowego |
-
2015
- 2015-09-15 PL PL21169154.8T patent/PL3929303T3/pl unknown
- 2015-09-15 PL PL15771837T patent/PL3194618T3/pl unknown
- 2015-09-15 US US14/855,229 patent/US10407730B2/en active Active
- 2015-09-15 CN CN201580061761.0A patent/CN107208132A/zh active Pending
- 2015-09-15 CA CA2959670A patent/CA2959670C/en active Active
- 2015-09-15 DK DK15771837.0T patent/DK3194618T3/da active
- 2015-09-15 ES ES15771837T patent/ES2881474T3/es active Active
- 2015-09-15 EP EP21169154.8A patent/EP3929303B1/en active Active
- 2015-09-15 AU AU2015317893A patent/AU2015317893B2/en active Active
- 2015-09-15 JP JP2017533744A patent/JP6782700B2/ja active Active
- 2015-09-15 ES ES21169154T patent/ES3013599T3/es active Active
- 2015-09-15 KR KR1020177010086A patent/KR102762958B1/ko active Active
- 2015-09-15 KR KR1020257003150A patent/KR20250021631A/ko active Pending
- 2015-09-15 WO PCT/US2015/050274 patent/WO2016044330A1/en not_active Ceased
- 2015-09-15 EP EP15771837.0A patent/EP3194618B1/en active Active
- 2015-09-15 MX MX2017003370A patent/MX386919B/es unknown
- 2015-09-15 DK DK21169154.8T patent/DK3929303T3/da active
-
2017
- 2017-03-01 IL IL250867A patent/IL250867B/en active IP Right Grant
- 2017-03-14 MX MX2021012347A patent/MX2021012347A/es unknown
-
2019
- 2019-08-01 US US16/528,864 patent/US11168372B2/en active Active
-
2020
- 2020-10-20 JP JP2020175701A patent/JP7157788B2/ja active Active
-
2021
- 2021-03-09 IL IL281355A patent/IL281355B/en unknown
- 2021-08-06 AU AU2021212151A patent/AU2021212151B2/en active Active
- 2021-11-08 US US17/521,205 patent/US12258633B2/en active Active
-
2023
- 2023-11-03 AU AU2023258444A patent/AU2023258444A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| BR112019004075A2 (pt) | métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit. | |
| WO2016044338A3 (en) | Methods and systems for diagnosing sleep disorders | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| MX2018009304A (es) | Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares. | |
| WO2017070114A3 (en) | Diabetes-related biomarkers and treatment of diabetes-related conditions | |
| MX2015012303A (es) | Un metodo no invasivo para medir el estres oxidativoy daño oxidativo de los biomarcadores cutaneos. | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| IN2014DE01077A (es) | ||
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| IN2014DN08537A (es) | ||
| NZ729773A (en) | Biomarkers for disease progression in melanoma | |
| GB2565740A (en) | Analysis of bodily fluids using infrared spectroscopy for the diagnosis and/or prognosis of cancer | |
| HK1232238A1 (zh) | 检测人类骨膜蛋白的新型测定 | |
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| GB2552271A (en) | A method for diagnosing lung cancer | |
| EP3502271A3 (en) | Blood biomarkers for appendicitis and diagnostics methods using biomarkers | |
| WO2016112174A3 (en) | Biomarkers of Sleep Deprivation and Cognitive Impairment | |
| WO2017156154A9 (en) | Compositions for characterizing development of esophageal adenocarcinoma in patients and methods of use thereof | |
| RU2014119032A (ru) | Способ диагностики латентного туберкулеза внелегочных локализаций |